GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death, according to a preliminary study being presented at the American Heart Association's annual Scientific Sessions, set ...

In addition to our pivotal program in hypertension, we are connecting the Explore-CKD Phase II clinical trial for ...

Already, Soriot is expecting potentially smaller growth in China next year as its blockbuster SGLT2 inhibitor Farxiga is ...

Greetings. Welcome to Mineralys third-quarter 2024 financial results conference call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce Dan ...

A recent study has shown that the weight-loss drug Ozempic, along with other medications in its class, may significantly ...

"Canagliflozin was linked to enhanced iron utilization and elevated hemoglobin levels in adults with type 2 diabetes and ...

The Prescription Drug User Fee Act date refers to the deadline set by the FDA for reviewing a NDA or Biologics License Application.

TUESDAY, Nov. 12, 2024 (HealthDay News) -- For patients with nephrolithiasis, sodium-glucose cotransporter-2 (SGLT-2) ...

FDA approved the Varipulse pulsed field ablation (PFA) platform for drug refractory paroxysmal atrial fibrillation, Johnson & ...

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA™ FDA Advisory Committee Meeting; PDUFA Goal Date December 20, ...